Pfizer's Q1 2022 earnings showcase significant revenue growth, driven by strong performance of Comirnaty and Paxlovid. The company reaffirms its full-year financial outlook, demonstrating confidence in its portfolio and strategic direction.
Q1 2022 revenues reached $25.7 billion, reflecting an 82% operational growth.
Reported diluted EPS was $1.37, and adjusted diluted EPS was $1.62, including a $0.05 negative impact for acquired in-process R&D expenses.
Full-year 2022 financial guidance reaffirmed for revenues of $98.0 to $102.0 billion.
Full-year 2022 adjusted diluted EPS guidance revised to a range of $6.25 to $6.45, reflecting an accounting policy change.
Pfizer reaffirms its full-year 2022 revenue guidance of $98.0 to $102.0 billion and revises adjusted diluted EPS guidance to $6.25 to $6.45, reflecting operational increases offset by foreign exchange impacts and accounting policy changes.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance